Genetically Modified Cells TRIZ Cases

A cocultured cellular system uses light-sensitive proteins to trigger ion efflux for precise cardiomyocyte action potential measurement.

Engineered mesenchymal stem cell line produces hypertrophic cartilage graft material through controlled BMP-2 expression.

Sleeping Beauty transposon system identifies Aak1 and Crtc3 genes to enhance T cell trafficking into solid tumors.

Small molecules modulate the JAK-STAT pathway to dedifferentiate somatic cells, bypassing genetic modification risks and improving induction efficiency.

Automated imaging replaces manual microscopy to measure target cell growth, resolving the trade-off between screening throughput and measurement precision.

Isolate multipotent adult stem cells using specific surface antigen markers for targeted identification.

Mutated Bcl-2-EEE genes decouple cell lifespan from density, resolving unpredictable yields while cutting adaptation time.

Gene editing removes SIGLEC15 from sentinel lymph node T cells, restoring cytokine release to counter cancer-derived immune suppression.

Silencing MHC molecules on allogeneic T cells prevents host rejection and graft-versus-host disease, enabling standardized cancer immunotherapy.

CRISPR knockout of SIT1, BST2, and PD-1 in T cells overcomes tumor microenvironment immunosuppression.

C to G point mutations in the hCMV-MIE promoter sequence maintain high polypeptide yields.

Unequal DNA copy numbers boost antibody yields without increasing transfection complexity.

Ricinus communis agglutinin I selection isolates CHO cells with enhanced GnT1 activity, extending circulatory half-life of therapeutic glycoproteins.

Senescence inhibitors dampen inflammatory responses during hematopoietic stem cell gene editing.

Culturing peripheral blood mononuclear cells with anti-CD3 antibody and interleukin 2 enables efficient iPS cell generation.

Modified NK-92 cells maintain stable CD16 expression during activation to resolve the contradiction between cytolytic activity and lack of ADCC capability.

Engineered HEK293 cell lines use inducible recombinases to control mitogen and protein expression phases.

Transient siRNA knockdown of lineage-defining transcription factors reprograms somatic cells, overcoming low efficiency and safety risks of viral vectors.

Reducing B3gnt5 enzyme activity lowers immunogenic glycan expression on porcine cells, mitigating immune rejection during xenotransplantation.

Targeted gene integration into hiPSCs creates rapid Alzheimer's models, replacing slow transgenic mice to improve drug screening predictability.

Small molecule inhibitor mixture drives human fibroblast reprogramming into induced pluripotent stem cells.

Episomal vectors reprogram Epstein-Barr virus immortalized B cells to generate patient-specific induced pluripotent stem cells free from exogenous elements.

Nucleotide-encoded transcription factors bypass pluripotent intermediaries to accelerate transdifferentiation efficiency for cardiac repair.

Purified 30S ribosomal proteins reprogram somatic cells into pluripotent states without genetic modification.

Engineered microbial chassis couples with plant ammonium transporters to boost nitrogen fixation efficiency through seed-coated inoculation.

Novel GPC3-targeting bispecific antibodies recruit immune cells to kill hepatocellular carcinoma cells.

Immortalized porcine kidney macrophages overcome low infection susceptibility of primary cells, enabling efficient virus proliferation and vaccine production.

RNA interference silences the DPH2 gene transcript in human cells to confer resistance against diphtheria toxin.

Reprogramming non-hair follicle stem cells into induced hair follicle stem cells using specific genetic markers and reagents.

Viral vectors deliver growth genes to immortalize crustacean muscle and fat cells, bypassing complex genome assembly challenges.

Ferric ammonium citrate supplies iron to myeloma cells in a transferrin-free medium, preventing rapid oxidation and precipitation.

Electroporation introduces CD16-V158 and CCR7 transgenes into NK cells, resolving viability loss from viral methods while boosting tumor homing.

Dexamethasone and SMER28 in the culture medium amplify erythroid progenitors, resolving contradictions between rapid maturation and production yield.

A mediator structure bridges the receptor and soluble antigen, resolving stability trade-offs while enabling targeted cytolytic activity.

Reprogramming Wharton's jelly cells with HATH1 and HES inhibitors to regenerate functional hair cells for hearing restoration.

Engineered lymphocytes reduce immunogenicity and improve delivery efficiency by transferring gene editing reagents through perforin-induced membrane pores.

CD24-expressing cell-derived particles modulate immune responses to reduce cytokine levels and lung damage in acute respiratory distress syndrome.

Modifying AAV cap gene sequences alters VP1, VP2, and AAP protein expression levels to enhance recombinant adeno-associated virus production yields.

Non-integrating Epstein-Barr virus episomal vectors generate induced pluripotent stem cells free of exogenous genetic elements, eliminating mutagenesis risks.

RAG-mediated V(D)J targeting inserts genes at safe harbor loci, eliminating insertional mutagenesis risks from promiscuous vectors.

A modular docosahexaenoic acid synthase enzyme catalyzes de novo polyunsaturated fatty acid synthesis using malonyl-CoA substrates.